ID   LD692
AC   CVCL_EJ20
DR   cancercelllines; CVCL_EJ20
DR   Cosmic; 943739
DR   IARC_TP53; 10280
DR   Wikidata; Q54902375
RX   PubMed=9850064;
RX   PubMed=29732388;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=9850064).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_EJ19 ! LD660
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 19-12-24; Version: 12
//
RX   PubMed=9850064;
RA   Markl I.D.C., Jones P.A.;
RT   "Presence and location of TP53 mutation determines pattern of
RT   CDKN2A/ARF pathway inactivation in bladder cancer.";
RL   Cancer Res. 58:5348-5353(1998).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//